Deals > All

East Germany North Germany South Germany West Germany Austria Germany Switzerland [ # 12 & 35 ]

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3067 | Ordered by Date (descending)
1 2 3 ... 29 30 31

Deal: Collaboration or Financing	Date
Memo Therapeutics–SEVERAL: investment, 201507 financing round Series A CHF2.3m from Swiss investors incl EVA Basel + Redalpine + Zürcher Kantonalbank	2015-07-22
Allergan–Molecular Partners: ophthalmics, 201507– collab expansion of DARPin alliance in ophthalmology	2015-07-21
Accurate Mass Scientific–CovalX: mass spectrometry, 201507– collab AMS new Australian distributor of CovalX High-Mass systems + CRO analytics services	2015-07-15
AdvanDx–OpGen: investment, 201507 merger acquisition by AdvanDx for 682k shares of OpGen common stock	2015-07-14
Actelion–Max Planck: vaccine technology, 201506 license excl synthetic carbohydrate vaccines for new Vaxillion joint venture from + with Max Planck	2015-06-26
Vaxxilon–Actelion: investment, 201506 founding w Max Planck + Actelion as majority owner w committed funding of €30m over 4y in tranches	2015-06-26
ViraTherapeutics–Austria (govt): investment, 201506 financing round Series A 1st closing totalling €3.6m incl co-investor aws	2015-06-23
ViraTherapeutics–Boehringer: investment, 201506 financing round Series A 1st closing totalling €3.6m co-led by BIVF + EMBL Ventures	2015-06-23
ViraTherapeutics–EMBL: investment, 201506 financing round Series A 1st closing totalling €3.6m co-led by BIVF + EMBL Ventures	2015-06-23
Juno Therapeutics–Editas Medicine: cancer immunotherapy, 201505– strategic alliance to develop CAR-T + engineered TCR therapies	2015-05-27
Merus–EU (govt): grant, 201505– Eureka Eurostars grant totalling €2.1m for Merus + Selexis to develop bispecific antibody drugs for colorectal cancer	2015-05-20
Merus–Selexis: antibody cancer drug, 201505– collab combining Oligoclonics + SUREtechnology to develop bispecific antibody drugs for colorectal cancer	2015-05-20
Selexis–EU (govt): grant, 201505– Eureka Eurostars grant totalling €2.1m for Merus + Selexis to develop bispecific colorectal cancer antibody drugs	2015-05-20
Curasan–SEVERAL: investment, 201505 capital increase €1m with 730k new shares at €1.4/share	2015-05-19
Novartis–BioQuiddity: pharmaceutical, 201505– excl license + supply for ready-to-use ropivacaine + proponal infusions to Sandoz in US	2015-05-13
Cytos Biotechnology–SEVERAL: investment, 201505 conversion of all outstanding convertible bonds into 77.49m new shares making Cytos debt free	2015-05-08
Arcus Biosciences–Novartis: investment, 201505 financing round Series A totalling $49.7m incl co-investor Novartis	2015-05-01
Arcus Biosciences–SEVERAL: investment, 201505 financing round Series A $49.7m incl F&F + Column Group + Foresite Capital + Novartis + Celgene	2015-05-01
Auris Medical–SEVERAL: investment, 201505 public offering $25m with 5.275m common shares at $4.75/share	2015-05-01
Cyclenium–Haplogen: virostatic agents, 201505– collab drug discovery small molecule macroycle inhibitors using CMRT technology	2015-05-01
Strüngmann Group–Formycon: biosimilar, 201505– license ww excl to Eylea biosimilar FYB203 to Santo Holding GmbH	2015-05-01
Formycon–SEVERAL: investment, 201504 capital increase €11.1m with 435.9k new shares at €25.5/share to instituional investors + family offices	2015-04-16
Menarini–4SC: resminostat, 201504– collab license + developm €95m upfront + milestones + royalties for Asia-Pacific excl JP Menarini Asia-Pacific	2015-04-14
Blueberry Therapeutics–SEVERAL: investment, 201504 financing round $1.75m from UK + Swiss investors	2015-04-08
Caribou Biosciences–SEVERAL: investment, 201504 financing round Series A $11m incl Fidelity Biosciences + Novartis + Mission Bay Capital et al	2015-04-02
Sumitomo–Evolva: agri bioactives, 201503– collab excl developm + commercialisation of ingredient class by Valent BioSciences	2015-03-26
Mologen–SEVERAL: investment, 201503–201504 capital increase €28.3m with 5.66m new shares at €5/share	2015-03-24
Sanofi–Evotec: drug discovery, 201503– collab strategic alliance 5 years minimum €250m with €40m upfront	2015-03-20
AdnaGen–Qiagen: investment, 201503 acquisition of assets by Qiagen via newly established Qiagen Hannover GmbH	2015-03-16
Boehringer–Artes Biotechnology: vaccine technology, 201503– collab using Hansenula expression system + Metavax platform for animal vaccine development	2015-03-16
Tokai Pharmaceuticals–Qiagen: molecular companion diagnostics, 201503– collab developm + commercialistion of CTC-based CDx for galeterone	2015-03-16
Addex–SEVERAL: investment, 201503 private placement CHF2.8m with 1.53m new shares led by Herculis Partners SA	2015-03-09
CureVac–Gates Foundation: investment, 201503 equity investment €46m by Gates Foundation	2015-03-05
CureVac–Hopp Group: investment, 201503 equity investment €21m by dievini Hopp BioTech Holding	2015-03-05
CureVac–SEVERAL: investment, 201503 private placement €67m from Gates Foundation + dievini Hopp BioTech	2015-03-05
Macrolide–Bertarelli Group: investment, 201503 financing round Series A totalling $22m inc co-lead investor Gurnet Point Capital	2015-03-04
Macrolide–GSK: investment, 201503 financing round Series A totalling $22m inc co-lead investor SROne	2015-03-04
Macrolide–Novartis: investment, 201503 financing round Series A totalling $22m inc co-lead investor Novartis Venture Fund	2015-03-04
Macrolide–Roche: investment, 201503 financing round Series A totalling $22m inc co-lead investor Roche Ventures	2015-03-04
Macrolide–SEVERAL: investment, 201503 financing round Series A $22m led by NVF + Gurnet Point + Roche Ventures + SR One	2015-03-04
OpGen–SEVERAL: investment, 201503–201505 IPO $17.1m+$2.565m with 2.85m+427.5k units consisting of 1 share + 1 warrant at $6/unit	2015-03-03
Pfizer–Genedata: bioinformatics, 201503– supply license to Genedata Biologics enterprise platform for Pfizer RnD Sites in US + Europe	2015-03-03
APR Applied Pharma Research–HBM: investment, 201503 acquisition of €na minority stake by HBM Partners	2015-03-01
Genenta Science–SEVERAL: investment, 201503 financing round Series A €10m	2015-03-01
Canbex Therapeutics–Ipsen: investment, 201502 Ipsen pays €6m upfront for option to acquire Canbex upon Ph2a completion of VSN16R in MS spasticity	2015-02-24
Prexton Therapeutics–Merck (DE): investment, 201502 financing round Series A totalling €8.7m incl returning founding + co-investor MS Ventures	2015-02-24
Prexton Therapeutics–SEVERAL: investment, 201502 financing round Series A €8.7m co-led by Sunstone Capital + Ysios Capital plus MS Ventures	2015-02-24
Prexton Therapeutics–Sunstone Capital: investment, 201502 financing round Series A totalling €8.7m incl co-lead investor Sunstone Capital	2015-02-24
Prexton Therapeutics–Ysios Capital: investment, 201502 financing round Series A totalling €8.7m incl co-lead investor Ysios Capital	2015-02-24
NBE Therapeutics–Boehringer: investment, 201502 financing round Series A totalling CHF3m led by Boehringer Ingelheim Venture Fund	2015-02-20
Argenx–Lonza: gene expression system, 201502– license multi-product for GS Xceed System for production of therapeutic antibodies	2015-02-18
Boehringer–Genedata: bioinformatics, 201502– supply license to Genedata Biologics platform for BI RnD Sites in US + Europe	2015-02-18
Immunservice–High-Tech Gründerfonds: investment, 201502 financing round Series C incl existing investor HTGF	2015-02-18
Immunservice–SEVERAL: investment, 201502 financing round Series C from Michael Otto + Helmut Ponath + Hubertus-Wald-Stiftung + HTGF + Hartwig Huland	2015-02-18
AC Immune–Michael J Fox Foundation: grant, 201502 research grant €na for developm of PET tracers for alpha-synuclein protein in Parkinson diagnosis	2015-02-12
Exquiron Biotech–SAMDI Tech: drug discovery services, 201502– collab mutually co-promotion of respective services in Europe + North America	2015-02-08
R2R Biofluidics project–EU (govt): grant, 201502–201901 H2020 grant €6.4m out of total budget of €7.9m	2015-02-01
ASPEC Technologies–CovalX: mass spectrometry, 201501 collab existent ASPEC is distributor of CovalX High-Mass systems in China	2015-01-15
Boehringer–Vanderbilt Univ: Ras inhibitors, 201703– collab expansion r+d small-molecule KRAS inhibitors for cancer	2015-01-13
GenePOC–Debiopharm: investment, 201501 financing round led by Debiopharm Diagnostics + Emerillon Capital	2015-01-13
GenePOC–SEVERAL: investment, 201501 financing round led by Debiopharm Diagnostics + Emerillon Capital	2015-01-13
Addex–United States (govt): ADX71441, 201501– collab NIAAA to evaluate ADX71441 in preclinical models of alcohol use disorder	2015-01-07
OnCore BioPharma–Cytos Biotechnology: VLP technology, 201501– license to OnCore excl for use of VLP platform in treatm + prevention of HBV infections	2015-01-06
Provendis–TVM: venture capital, 201501– collab support in project evaluation + financing by TVM Capital Life Science for projects of Provendis	2015-01-06
Atomwise–SEVERAL: investment, 2015 seed financing round incl Y Combinator + Khosla Ventures + DJF	2015-01-01
Biocentric–Hain Lifescience: investment, 2015 acquisition of Biocentric by Hain	2015-01-01
EffRx–SEVERAL: investment, 201501 financing round CHF2.3m from existing investors	2015-01-01
GreenBone–SEVERAL: investment, 2015 seed financing round €3m from ZernikeMeta Ventures + Italian Angels for Growth + private investors	2015-01-01
IFM Therapeutics–Atlas Venture: investment, 2015 seed funding by Atlas Venture	2015-01-01
Jecure Therapeutics–Versant Ventures: investment, 2015 seed financing from founding investor Versant Ventures	2015-01-01
KBI BioPharma–JSR Corp: investment, 2015 acquisition of KBI BioPharma Inc by JSR Corp	2015-01-01
Kurma–SEVERAL: investment, 2015 final closing €35m of Kurma Diagnostics Fund (KDx)	2015-01-01
Novartis–Fraunhofer: cell therapy production, 201501– collab developm of production capacity for Kymriah in Europe at Fraunhofer IZI	2015-01-01
Novartis–Fraunhofer: cell therapy production, 201808– service supply production of Kymriah in Europe by Fraunhofer IZI	2015-01-01
Numares–SHS: investment, 2015 existent SHS Gesellschaft für Beteiligungsmanagement is main shareholder	2015-01-01
Oncgnostics–MDxHealth: PCR technology, 201501– license ww non-excl for MSP technology for cervical cancer diagnostics to Oncgnostics	2015-01-01
Proteomedix–SEVERAL: investment, 201501 2nd closing of financing round Series B CHF1m bringing total round to CHF4.2m	2015-01-01
Roche–4D Molecular Therapeutics: gene delivery technology, 2015– collab research	2015-01-01
VIB–Lipotype: mass spectrometry services, 2015– collab supply of shotgun lipidomics services by Lipotype to researchers at VIB	2015-01-01
ViraTherapeutics–Austria (govt): investment, 2015c financing €1.6m from FFG + aws seed financing programme	2015-01-01
Pieris–Ally Bridge Group: investment, 201412 private placement totalling $13.56m incl investor ABG	2014-12-18
Annexon–Clarus Ventures: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Clarus Ventures	2014-12-15
Annexon–Novartis: investment, 201412 financing round Series A-1 totaliing $34m incl lead investor NVF	2014-12-15
Annexon–Satter Investment Management: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Satter	2014-12-15
Annexon–SEVERAL: investment, 201412 financing round Series A-1 $34m led by NVF + incl Satter Investment + Clarus Ventures	2014-12-15
Tiziana–Novimmune: therapeutic antibody, 201412– license to foralumab (NI-0401) to Tiziana	2014-12-01
Pepperprint–Sciomics: microarray technology, 201411– collab distribution + marketing for antibody characterisation + biomarker discovery	2014-11-18
Roche–NewLink Genetics: cancer drugs, 201410– collab drug discovery IDO/TDO inhibitors with Genentech	2014-10-16
Corgenix Medical–Orgentec: investment, 201409–201503 acquisition of Corgenix for $16m in cash by Orgentec Diagnostika	2014-09-01
Ipsen–MHH: rec botulinum neurotoxin, 201409– collab r+d with Thomas Binz at Institute for Physiological Chemistry at MHH	2014-09-01
i3 Membrane–SEVERAL: investment, 201408 investment by HTGF + Innovationsstarter Fonds Hamburg	2014-08-01
Riboxx–SEVERAL: investment, 201407–201501 crowdfunding €1m via Seedmatch	2014-07-30
Geisinger–Indivumed: tissue bank, 201407– collab to create cancer research biobanks at Geisinger + Indivumed	2014-07-15
AbbVie–Apogenix: TRAIL receptor agonists, 201407 aquisition of ww rights to all TRAIL receptor agonists of Apogenix by AbbVie	2014-07-01
B Braun–CeGaT: personalised medicine, 201406 collab establishment of B Braun CeGaT LLC in Pennsylvania	2014-06-01
Novartis–Ophthotech: pegpleranib, 201405– excl license + commercialisation agreem outside of US	2014-05-01
Essen BioScience–SFW Capital Partners: investment, 201405 strategic investment in Essen BioScience by SFW	2014-04-15
Roche–Oryzon Genomics: LSD1 inhibitors, 201605–201707 collab extension developm of ORY-1001 TERMINATED 7/17	2014-04-07
Synaffix–Aravis: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital	2014-02-18
Synaffix–BioGeneration Ventures: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital	2014-02-18

1 2 3 ... 29 30 31

Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)